Scott Schoenhaus
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
84
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Scott Schoenhaus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus | Initiates: Overweight | $47 | $27.78 | +69.19% | 1 | Jul 29, 2024 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $7 → $5 | $2.73 | +83.15% | 3 | Jul 11, 2024 | |
| ABSI Absci | Maintains: Overweight | $8 → $6 | $3.92 | +53.06% | 4 | Jul 11, 2024 | |
| ALIT Alight | Maintains: Overweight | $11 → $10 | $6.80 | +47.06% | 5 | Jul 11, 2024 | |
| CERT Certara | Maintains: Overweight | $23 → $20 | $10.25 | +95.12% | 3 | Jul 11, 2024 | |
| LFMD LifeMD | Maintains: Overweight | $12 → $10 | $4.32 | +131.48% | 2 | Jul 11, 2024 | |
| PHR Phreesia | Maintains: Overweight | $27 → $25 | $18.47 | +35.35% | 5 | Jul 11, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Overweight | $16 → $12 | $6.40 | +87.50% | 5 | Jul 11, 2024 | |
| SDGR Schrödinger | Maintains: Overweight | $30 → $25 | $17.99 | +38.97% | 3 | Jul 11, 2024 | |
| HQY HealthEquity | Maintains: Overweight | $95 → $100 | $86.33 | +15.83% | 3 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $15.00 | - | 5 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $14.26 | - | 8 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $7.70 | - | 4 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 | $6.19 | +45.40% | 4 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $232 → $250 | $212.78 | +17.49% | 14 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $48.67 | - | 8 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $38.07 | +57.60% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Weight | n/a | $9.21 | - | 4 | Sep 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $180 → $250 | $209.16 | +19.53% | 2 | Apr 16, 2021 |
Simulations Plus
Jul 29, 2024
Initiates: Overweight
Price Target: $47
Current: $27.78
Upside: +69.19%
AbCellera Biologics
Jul 11, 2024
Maintains: Overweight
Price Target: $7 → $5
Current: $2.73
Upside: +83.15%
Absci
Jul 11, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $3.92
Upside: +53.06%
Alight
Jul 11, 2024
Maintains: Overweight
Price Target: $11 → $10
Current: $6.80
Upside: +47.06%
Certara
Jul 11, 2024
Maintains: Overweight
Price Target: $23 → $20
Current: $10.25
Upside: +95.12%
LifeMD
Jul 11, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $4.32
Upside: +131.48%
Phreesia
Jul 11, 2024
Maintains: Overweight
Price Target: $27 → $25
Current: $18.47
Upside: +35.35%
Recursion Pharmaceuticals
Jul 11, 2024
Maintains: Overweight
Price Target: $16 → $12
Current: $6.40
Upside: +87.50%
Schrödinger
Jul 11, 2024
Maintains: Overweight
Price Target: $30 → $25
Current: $17.99
Upside: +38.97%
HealthEquity
Jun 5, 2024
Maintains: Overweight
Price Target: $95 → $100
Current: $86.33
Upside: +15.83%
May 10, 2024
Downgrades: Sector Weight
Price Target: n/a
Current: $15.00
Upside: -
Apr 10, 2024
Downgrades: Sector Weight
Price Target: n/a
Current: $14.26
Upside: -
Apr 10, 2024
Downgrades: Sector Weight
Price Target: n/a
Current: $7.70
Upside: -
Apr 10, 2024
Upgrades: Overweight
Price Target: $9
Current: $6.19
Upside: +45.40%
Mar 5, 2024
Maintains: Overweight
Price Target: $232 → $250
Current: $212.78
Upside: +17.49%
Oct 11, 2023
Downgrades: Sector Weight
Price Target: n/a
Current: $48.67
Upside: -
Aug 15, 2023
Initiates: Overweight
Price Target: $60
Current: $38.07
Upside: +57.60%
Sep 16, 2022
Initiates: Sector Weight
Price Target: n/a
Current: $9.21
Upside: -
Apr 16, 2021
Upgrades: Overweight
Price Target: $180 → $250
Current: $209.16
Upside: +19.53%